Colorectal Cancer Articles

Expert Discusses PD-1 Success in MSI-H Colorectal Cancer
Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.
Atezolizumab/Bevacizumab Combo Attains 90% DCR in MSI-High mCRC
Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.
Napabucasin Linked With Objective Responses in Advanced CRC
As many as one-third of patients with treatment-resistant colorectal cancer attained objective responses with the stemness inhibitor napabucasin plus FOLFIRI chemotherapy with or without bevacizumab, according to evaluable results of a study presented at the 2017 Gastrointestinal Cancers Symposium.
Enhanced Recovery Program Improves Outcomes After Colorectal Cancer Surgery
The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.
The incidence of hand-foot syndrome was decreased following first-line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer, according to findings from the phase III SALTO study that were presented at the 2017 European Cancer Congress.
Treatment, Diagnosis Disparities Among Hospitals Impacts Survival of Patients With Colorectal Cancer and Peritoneal Metastases
Patients receiving the same diagnosis, colorectal cancer with synchronous peritoneal metastases, were offered different treatments that led to dramatically different outcomes based upon the institution in which they were diagnosed. Findings presented at the 19th European Cancer Congress revealed underutilization of a highly effective treatment, due to a lack of referral.
Vemurafenib Adds to PFS in BRAF-mutant mCRC
Adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with BRAF-mutant metastatic colorectal cancer.
Nivolumab Activity Affirmed in Microsatellite Instability-High mCRC
The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.
Trend Toward Better PFS With Four-Drug CRC Regimen
Patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy, a randomized trial showed.
Watch-and-Wait Approach a Potential Option for Patients With Rectal Cancer
A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer.
Publication Bottom Border
Border Publication